

The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Withdrawn) A method for suppressing accelerated repopulation of cancer cells during radiation therapy, comprising the step of
delivering to cancer cells an effective dose of an expressible nucleic acid molecule encoding a mutant epidermal growth factor receptor.
2. (Withdrawn) The method of claim 1 wherein said mutant epidermal growth factor receptor is EGFR-CD533.
3. (Withdrawn) The method of claim 1 wherein said expressible nucleic acid molecule is a DNA molecule.
4. (Withdrawn) The method of claim 1 wherein said expressible nucleic acid molecule is in an expression cassette.
5. (Withdrawn) The method of claim 4 wherein said expression cassette is Ad-EGFR-CD533.
6. (Withdrawn) The method of claim 1 wherein said expressible nucleic acid molecule is an RNA molecule.
7. (Withdrawn) The method of claim 1 wherein said step of delivering is accomplished by administration to a patient in need thereof.
8. (Withdrawn) The method of claim 7 wherein said administration is oral.
9. (Withdrawn) The method of claim 7 wherein said administration is systemic.

10. (Withdrawn) The method of claim 7 wherein said administration is *in situ* at the cancer locus.

11. (Withdrawn) The method of claim 7 wherein said administration is carried out via a method selected from the group consisting of administering a viral vector, administering liposomes, and direct injection of nucleic acid.

12. (Withdrawn) The method of claim 1 wherein said cancer cells are mammary cancer cells.

13. (Withdrawn) The method of claim 1 wherein said cancer cells are glioma cells.

14. (Withdrawn) The method of claim 1 wherein said cancer cells express epidermal growth factor receptor.

15. (Withdrawn) A therapeutic agent comprising,

an effective dose of an expressible nucleic acid molecule encoding a mutant epidermal growth factor receptor and a carrier.

16. (Withdrawn) The therapeutic agent of claim 15, wherein said mutant epidermal growth factor receptor is EGFR-CD533.

17. (Withdrawn) The therapeutic agent of claim 15, wherein said expressible nucleic acid molecule is in an expression cassette.

18. (Withdrawn) The therapeutic agent of claim 17, wherein said expression cassette is Ad-EGFR-CD533.

19. (Currently amended) A method for radiosensitizing cancer cells, comprising the step of delivering to said cancer cells an effective dose of an expressible nucleic acid encoding a dominant negative mutant epidermal growth factor receptor.

20. (Currently amended) The method of claim 19, wherein said dominant negative mutant epidermal growth factor receptor is EGFR-CD533.

21. (Original) The method of claim 19 wherein said expressible nucleic acid molecule is a DNA molecule.

22. (Original) The method of claim 19 wherein said expressible nucleic acid molecule is in an expression cassette.

23. (Original) The method of claim 22 wherein said expression cassette is Ad-EGFR-CD533.

24. (Original) The method of claim 19 wherein said expressible nucleic acid molecule is an RNA molecule.

25. (Original) The method of claim 19 wherein said step of delivering is accomplished by administration to a patient in need thereof.

26. (Original) The method of claim 25 wherein said administration is oral.

27. (Original) The method of claim 25 wherein said administration is systemic.

28. (Original) The method of claim 25 wherein said administration is *in situ* at the cancer locus.

29. (Original) The method of claim 25 wherein said administration is carried out via a method selected from the group consisting of administering a viral vector, administering liposomes, and direct injection of nucleic acid.

30. (Original) The method of claim 19 wherein said cancer cells are mammary cancer cells.

31. (Original) The method of claim 19 wherein said cancer cells are glioma cells.

32. (Original) The method of claim 19 wherein said cancer cells express epidermal growth factor receptor.

33. (New) A method for radiosensitizing cancer cells comprising the step of
delivering to said cancer cells an effective dose of an expressible nucleic acid encoding a
carboxy terminal truncated mutant epidermal growth factor receptor.

34. (New) A method for inhibiting the radiation-induced proliferations of cancer cells comprising
the step of

directly delivering to said cancer cells an effective dose of an expressible nucleic acid
molecule encoding a carboxy terminal truncated mutant of EGFR.

35. (New) A method for inhibiting the radiation-induced proliferations of cancer cells comprising
the step of

delivering to said cancer cells an effective dose of an expressible nucleic acid molecule
encoding a carboxy terminal truncated mutant of EGFR.